Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Why this matters Trials no longer need to focus solely on complete abstinence
They don't address the root cause
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
AI-driven bioactive peptide discovery of next-generation metabolic biotherapeutics
This adds 30 seconds to the reconstitution workflow and eliminates the "wait, when did I open this?" question that's the most-cited cause of accidentally running past 28 days
US$ 25.87
US$ 28.59
US$ 28.29